Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.
about
MicroRNAs and their target gene networks in breast cancerDesign, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domainIQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistanceTargeting androgen receptor in estrogen receptor-negative breast cancerPI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancerActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximabCritical appraisal of trastuzumab in treatment of advanced stomach cancerErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylationNeoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumabMore than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future HoldsRole of HER2 in NSCLCInducing Oncoprotein Degradation to Improve Targeted Cancer TherapyA paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapyEvidence for archaic adaptive introgression in humansProtein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerTargeting of erbB3 receptor to overcome resistance in cancer treatmentCannabinoids as therapeutic agents in cancer: current status and future implicationsProfile of neratinib and its potential in the treatment of breast cancerTargeting Hsp90 in urothelial carcinomaRegulation of ERBB3/HER3 signaling in cancerDual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugsOrchestration of ErbB3 signaling through heterointeractions and homointeractions.Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodiesUnderstanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and OpportunitiesMy Cousin, My Enemy: quasispecies suppression of drug resistanceThe Mediator Kinase Module Restrains Epidermal Growth Factor Receptor Signaling and Represses Vulval Cell Fate Specification in Caenorhabditis elegansEngineering of bispecific affinity proteins with high affinity for ERBB2 and adaptable binding to albuminCellular effects of HER3-specific affibody moleculesA haplotype at STAT2 Introgressed from neanderthals and serves as a candidate of positive selection in Papua New GuineaµFBI: a microfluidic bead-based immunoassay for multiplexed detection of proteins from a µL sample volumeThe ER structural protein Rtn4A stabilizes and enhances signaling through the receptor tyrosine kinase ErbB3Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease.Dendritic cells transfected with Her2 antigen-encoding RNA replicons cross-prime CD8 T cells and protect mice against tumor challenge.Molecular imaging in pancreatic cancer--a roadmap for therapeutic decisions.Profiling the HER3/PI3K pathway in breast tumors using proximity-directed assays identifies correlations between protein complexes and phosphoproteins.
P2860
Q21195211-615298A5-B6B8-4B8B-8CAD-FF8ECD834C2FQ24293331-2B497D73-F782-4762-9C84-0F1DEF966028Q24309891-40E9D23B-3932-48BD-B162-AF7F35360A06Q24312457-ED543EF8-DB49-4F40-BBC6-836D03E3F6A8Q24338724-1E9588FA-E55E-47AA-89EB-38E3F76611EBQ24600031-6993A7E7-4FE7-4816-B075-F8B365A04A07Q24604411-ACEA40B8-49D0-4740-961B-5E449B95FA1DQ24621754-B8CB0BF5-D456-46E1-9FFE-BE6D5C46802EQ26764879-4226A597-3532-4067-A943-8F3D98BEA801Q26781662-E2447407-EEAD-48BA-BAF4-F8ABBC404C81Q26781683-3DA2F9D8-094C-4C1F-9E06-32D5CAE126E0Q26782145-BED13C2D-0B7F-46F6-B112-167AAACADA8FQ26824462-FD38144A-1EB8-44A4-92E4-EF3A0BD9D78AQ26830001-F21725A3-D996-45E9-892C-779B20C681A4Q26852215-310EE58B-F306-4F44-B62E-B1E19DAFA79AQ26864668-6F16C0BD-5005-48BA-B3F9-4ACBB4B4CCE5Q26866298-3BF90842-73BA-4673-A215-4ECFFCB2A2D4Q27012540-A943AC22-33BC-4403-8A10-9BBAF7B8F2B9Q27023406-4ADB96DB-D1E0-4F44-8AB6-EAB7C3FCCCD2Q27024334-C9957286-4326-4986-AF05-C80FC1DAEC2FQ27303674-E9A23B54-16DA-4C61-A14D-C9A38415C0ADQ27306737-CD9CA4CA-B845-44CE-8B0E-A6996D4D0BDEQ27646596-DFFD8049-D21E-4419-B12A-5882EDA9E606Q27683825-221B46A5-A4E5-4FAD-97BC-88DA12F6D7FAQ27691330-EF8D2FC8-DAE8-4777-B1A8-EFE08F253615Q27851691-C0830463-F7BD-4D89-B28C-8F11315F97AFQ27851705-DF8CE0C7-46B7-48EC-8C66-74040CCEDBF8Q27853182-274C24E8-5757-4DC9-958F-241A8B5FD324Q28074619-75256929-7CE6-4F40-8003-D0B64C170DFAQ28076138-B0133AE9-C9EB-4B3A-A2B2-BD962618A0BCQ28271572-15E2DA5F-36DD-4C10-BAF5-6B545ADC5C8DQ28541561-EBD7F936-80B7-41BF-B8A0-505D165F9211Q28727774-857EC5BF-217F-4B7F-B96B-5FFA8B892F10Q28728528-7C339DAE-A50A-4369-A9D5-64E646149E67Q28749053-5AB7AE33-27AA-4367-9A92-37AD7379533CQ28910204-A40A9D3B-42F9-405E-BE73-D75D914F7AADQ30315828-F70BEB25-96A2-473B-B549-63744205700AQ30318566-FFB0D0DC-2977-496B-A3BA-F894CE1C0278Q30423854-0EE31D66-7259-4EA2-9365-FE80599AAB60Q30997919-01E498FC-A65C-41CA-B2C8-8EA2760D3464
P2860
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.
@en
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.
@nl
type
label
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.
@en
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.
@nl
prefLabel
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.
@en
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.
@nl
P356
P1476
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
@en
P2093
José Baselga
P2888
P304
P356
10.1038/NRC2656
P407
P577
2009-06-18T00:00:00Z